JPH06508988A - - Google Patents

Info

Publication number
JPH06508988A
JPH06508988A JP50122393A JP50122393A JPH06508988A JP H06508988 A JPH06508988 A JP H06508988A JP 50122393 A JP50122393 A JP 50122393A JP 50122393 A JP50122393 A JP 50122393A JP H06508988 A JPH06508988 A JP H06508988A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP50122393A
Other versions
JP3533216B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9113809.9 priority Critical
Priority to GB9113809A priority patent/GB9113809D0/en
Application filed filed Critical
Priority to PCT/GB1992/001092 priority patent/WO1993000436A1/en
Publication of JPH06508988A publication Critical patent/JPH06508988A/ja
Application granted granted Critical
Publication of JP3533216B2 publication Critical patent/JP3533216B2/ja
Anticipated expiration legal-status Critical
Application status is Expired - Fee Related legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
JP50122393A 1991-06-26 1992-06-17 乳頭腫ウイルスl2蛋白 Expired - Fee Related JP3533216B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9113809.9 1991-06-26
GB9113809A GB9113809D0 (en) 1991-06-26 1991-06-26 Papillomavirus l2 protein
PCT/GB1992/001092 WO1993000436A1 (en) 1991-06-26 1992-06-17 Papillomavirus l2 protein

Publications (2)

Publication Number Publication Date
JPH06508988A true JPH06508988A (ja) 1994-10-13
JP3533216B2 JP3533216B2 (ja) 2004-05-31

Family

ID=10697369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50122393A Expired - Fee Related JP3533216B2 (ja) 1991-06-26 1992-06-17 乳頭腫ウイルスl2蛋白

Country Status (12)

Country Link
US (2) US6380157B1 (ja)
EP (1) EP0592480B1 (ja)
JP (1) JP3533216B2 (ja)
AT (1) AT179458T (ja)
AU (1) AU662910B2 (ja)
DE (2) DE69229050T2 (ja)
DK (1) DK0592480T3 (ja)
ES (1) ES2133322T3 (ja)
GB (1) GB9113809D0 (ja)
GR (1) GR3030716T3 (ja)
HK (1) HK1001309A1 (ja)
WO (1) WO1993000436A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508495A (ja) * 1999-09-07 2003-03-04 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規組成物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
GB9420146D0 (en) 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
DK0809700T3 (da) * 1994-10-07 2006-09-18 Univ Loyola Chicago Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
CA2211995A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
AU781653B2 (en) * 1996-07-30 2005-06-02 Transgene S.A. Pharmaceutical composition for treating papollomavirus tumour and infection
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
RU2282461C2 (ru) * 2000-06-26 2006-08-27 Стрессджен Байотекнолоджиз Корпорейшн Лечение инфекции, вызываемой вирусом папилломы человека
AT418997T (de) * 2000-07-06 2009-01-15 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
EP2280728B1 (en) 2008-05-26 2016-03-02 Cadila Healthcare Limited Combined measles-human papilloma vaccine
MX343908B (es) * 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
US9717783B2 (en) 2010-02-09 2017-08-01 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
US9533057B2 (en) 2010-02-09 2017-01-03 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
EP2802349B1 (en) * 2012-01-12 2017-12-06 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (en) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Immunogens of papilloma viruses
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508495A (ja) * 1999-09-07 2003-03-04 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規組成物
JP4689910B2 (ja) * 1999-09-07 2011-06-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規組成物

Also Published As

Publication number Publication date
GR3030716T3 (en) 1999-11-30
JP3533216B2 (ja) 2004-05-31
DK0592480T3 (da) 1999-11-08
GB9113809D0 (en) 1991-08-14
AU1985992A (en) 1993-01-25
EP0592480A1 (en) 1994-04-20
DK592480T3 (ja)
US6380157B1 (en) 2002-04-30
AU662910B2 (en) 1995-09-21
WO1993000436A1 (en) 1993-01-07
DE69229050D1 (de) 1999-06-02
EP0592480B1 (en) 1999-04-28
DE69229050T2 (de) 1999-10-21
ES2133322T3 (es) 1999-09-16
HK1001309A1 (en) 2000-04-20
AT179458T (de) 1999-05-15
US20020136736A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
JPH04118351U (ja)
JPH04138488U (ja)
JPH04119131U (ja)
JPH04128690U (ja)
DE9102609U1 (ja)
DE9104011U1 (ja)
JPH04116287U (ja)
JPH04133697U (ja)
DE9105304U1 (ja)
JPH04128320U (ja)
JPH07501242A (ja)
JPH06504463A (ja)
JPH06505185A (ja)
AU8148991A (ja)
EP0560989A4 (ja)
JPH04122641U (ja)
JPH04123184U (ja)
JPH04125492U (ja)
JPH04130269U (ja)
JPH04131241U (ja)
JPH04133653U (ja)
JPH07500184A (ja)
JPH04122488U (ja)
JPH04106624U (ja)
JPH04121866U (ja)

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040308

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090312

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees